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Abstract
Background: Cell surface carbohydrate antigens play a major role in the rejec‐
tion of porcine xenografts. The most important for human recipients are α‐1,3 Gal 
(Galactose‐alpha‐1,3‐galactose) causing hyperacute rejection, also Neu5Gc (N‐gly‐
colylneuraminic	acid)	and	Sd(a)	blood	group	antigens	both	of	which	are	likely	to	elicit	
acute vascular rejection given the known human immune status. Porcine cells with 
knockouts of the three genes responsible, GGTA1, CMAH and B4GALNT2, revealed 
minimal xenoreactive antibody binding after incubation with human serum. However, 
human leucocyte antigen (HLA) antibodies cross‐reacted with swine leucocyte an‐
tigen	class	 I	 (SLA‐I).	We	previously	demonstrated	efficient	generation	of	pigs	with	
multiple xeno‐transgenes placed at a single genomic locus. Here we wished to assess 
whether key xenoreactive antigen genes can be simultaneously inactivated and if 
combination with the multi‐transgenic background further reduces antibody deposi‐
tion and complement activation.
Methods: Multiplex	CRISPR/Cas9	gene	editing	and	somatic	cell	nuclear	transfer	were	
used to generate pigs carrying functional knockouts of GGTA1, CMAH, B4GALNT2 
and	SLA	class	 I.	 Fibroblasts	derived	 from	one‐	 to	 four‐fold	 knockout	 animals,	 and	
from multi‐transgenic cells (human CD46, CD55, CD59, HO1 and A20) with the four‐
fold knockout were used to examine the effects on human IgG and IgM binding or 
complement activation in vitro.
Results: Pigs were generated carrying four‐fold knockouts of important xenoreactive 
genes. In vitro assays revealed that combination of all four gene knockouts reduced 
human IgG and IgM binding to porcine kidney cells more effectively than single or 
double knockouts. The multi‐transgenic background combined with GGTA1 knockout 
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1  | INTRODUC TION
The global shortage of donated human organs and tissues has moti‐
vated efforts to genetically engineer pigs as a source of xenografts 
for human patients. A major advance in overcoming the immunolog‐
ical hurdles involved was identification of galactose‐α1,3‐galactose 
(α‐1,3Gal) as responsible for eliciting hyperacute rejection of pig tis‐
sue by old world primate recipients. Binding of preformed antibodies 
activates the host complement system leading to complete destruc‐
tion of the xenograft within minutes.1 Removing the main enzyme 
responsible for α‐1,3Gal synthesis by inactivating the porcine GGTA1 
gene significantly reduces hyperacute rejection, and this can be fur‐
ther improved by equipping GGTA1‐knockout pigs with human com‐
plement regulator transgenes.2‐6 The focus has now shifted onto 
delayed immune responses, notably those that target the endothe‐
lial lining of the graft vasculature. Acute vascular rejection occurs 
within a few days or weeks and is characterized by proinflammatory 
and procoagulatory activation of the vascular endothelium, com‐
plement activation, thrombotic microangiopathy and infiltration of 
innate immune cells into the graft.7,8 This response is also initiated 
by preformed antibodies,9 with evidence indicating a role for non‐
Gal porcine antigens including N‐glycolylneuraminic acid (Neu5Gc), 
synthesized by cytidine monophospho‐N‐acetylneuraminic acid hy‐
droxylase (CMAH),10‐12	and	surface	glycans	including	the	Sd(a)	blood	
group antigen produced by β‐1,4‐N‐acetyl‐galactosaminyl transfer‐
ase 2 (B4GALNT2).13‐15
Triple knockout of porcine GGTA1, CMAH and B4GALNT2 has 
been shown to significantly reduce human IgG and IgM antibody 
binding to porcine peripheral blood monocytes and red blood 
cells.15‐17 These studies also revealed that human leucocyte antigen 
(HLA) antibodies cross‐react with the porcine major histocompati‐
bility	complex	class	I,	also	known	as	swine	leucocyte	class	I	(SLA‐I)	
antigens,	highlighting	the	SLA‐I	complex	as	a	potential	target	for	fur‐
ther genetic modification.17
SLA	class	I	molecules	consist	of	a	heavy	α‐chain and a light β‐chain 
(β2‐microglobulin; B2M). The α‐chain, a transmembrane glycoprotein 
with three domains (α1, α2 and α3), is encoded by three different 
genes SLA‐1, ‐2 and ‐3.18 There are also a number of pseudogenes. 
The α1 and α2 domains interact to form the peptide‐binding do‐
mains and are therefore highly polymorphic. The α3 domain contains 
the cytoplasmic tail and has a constant region (encoded by exon 4) 
that is conserved between SLA‐1, ‐2 and ‐3. β2‐microglobulin does 
not contain a transmembrane region, is non‐covalently linked with 
the α‐chain and encoded by a highly conserved gene (B2M).19	SLA‐I	
has previously been ablated by targeting either porcine B2M,20 or 
the conserved region of the α‐chain within exon 4.21
To minimize antibody‐mediated xenograft rejection mechanisms, 
we produced pigs carrying four‐fold knockout of GGTA1, CMAH, 
B4GALNT2	and	either	the	SLA‐I	heavy	α‐chain or light β‐chain, and 
assessed how these affected binding of human IgG and IgM. The 
four‐fold knockouts were also combined with a five‐fold (human 
CD46, CD55, CD59, HO1 and A20) transgenic genotype, gener‐
ated previously and shown to reduce hyperacute and acute vas‐
cular rejection,5 and the effects on C3b/c and C4b/c complement 
activation tested.
2  | MATERIAL S AND METHODS
2.1 | Animal welfare
Animal experiments were approved by the Government of Upper 
Bavaria (permit number 55.2‐1‐54‐2532‐6‐13) and performed ac‐
cording to the German Animal Welfare Act and European Union 
Normative for Care and Use of Experimental Animals.
2.2 | Generation of guide RNA constructs
Specific	 gRNA	 oligonucleotides	 for	 GGTA1	 exon	 7	 (5′‐GTC 
GTGACCATAACCAGA‐3′),	 CMAH	 exon	 10	 (5′‐AGAAACTCCTGAA 
CTACA‐3′),	 B4GALNT2	 exon	 3	 (5′‐AGGAAAGCTATAACTTGG‐3′)	
and B2M	 exon	 1	 (5′‐TAGCGATGGCTCCCCTCG‐3′)	 or	 SLA‐I	 α‐
chain	 exon	 4	 (guide	 1	 5′‐CCAGGACCAGAGCCAGGACA‐3′	 and	
guide	 2	 5′‐CCAGAAGTGGGCGGCCCTGG‐3′),21	 18	 to	 20	 bp	 in	
length with additional BbsI overhangs were synthesized by MWG 
Eurofins, Germany. gRNA oligonucleotides were sub‐cloned into 
plasmid	 pSL1180	 that	 carries	 a	 0.2	 kb	 U6	 promoter	 followed	 by	
a BbsI restriction site and gRNA scaffold sequences. Restriction 
fragments were further sub‐cloned into the pX330 plasmid back‐
bone	(pX330‐U6‐Chimeric_BB‐CBh‐hSpCas9	was	a	gift	from	Feng	
Zhang; Addgene plasmid # 42230; http://n2t.net/addge ne:42230 ; 
RRID:Addgene_42230). The two final constructs contained 
three gRNAs specific for GGTA1, CMAH and B4GALNT2; either an 
alone reduced C3b/c and C4b/c complement activation to such an extent that further 
knockouts had no significant additional effect.
Conclusion: We showed that pigs carrying several xenoprotective transgenes and 
knockouts of xenoreactive antigens can be readily generated and these modifications 
will have significant effects on xenograft survival.
K E Y W O R D S
B2M, B4GALNT2, CMAH, complement regulators, GGTA1,	MHC‐I,	multiplex	CRISPR/Cas9	gene	
editing,	SLA‐I,	xenotransplantation
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additional gRNA specific for B2M, or two additional gRNAs for the 
SLA‐I	 α‐chain;	 a	 0.8	 kb	 chicken	 β hybrid promoter, followed by a 
SV40	nuclear	 localization	signal	 (NLS),	a	4.0	kb	hSpCas9	gene	 fol‐
lowed	by	a	 second	NLS	 signal,	 linked	via	 a	T2A	self‐cleaving	pep‐
tide to a 0.6 kb puromycin resistance cassette with a 0.2 kb bovine 
growth hormone polyadenylation (BGHpA) signal. A summary of the 
knockout	strategy	is	provided	in	Figure	S1.	An	alignment	of	SLA‐1,	
SLA‐2	and	SLA‐3	of	exon	4	with	the	sgRNA	target	site	is	provided	in	
Figure	S2.	Details	of	screening	primers	for	the	genomic	target	sites	
are	provided	in	Table	S1.
2.3 | Cell culture
Porcine kidney fibroblasts (PKF) were isolated and cultured as de‐
scribed previously.5 Transfection of gRNA/Cas9 plasmids was per‐
formed using Lipofectamine 2000 (Life Technologies). Twenty‐four 
hours after transfection, transiently transfected cells were selected 
using 1.5 µg/mL puromycin (InvivoGen) for 2 days.
2.4 | Magnetic bead selection and sequencing
α‐1,3Gal‐deficient cells were enriched by counter‐selection using 
streptavidin‐coated magnetic beads (Dynabeads, Life Technologies) 
and	biotin‐conjugated	isolectin	B4	(Enzo	Life	Science)	in	a	magnetic	
field. Gene editing was determined by sequencing across the gRNA 
target site (MWG Eurofins) and subsequent TIDE (tracking of indels 
by decomposition) analysis.22
2.5 | Somatic cell nuclear transfer
Nuclear transfer was performed as described previously.5 In short, 
donor cells were arrested at GO/G1 phase by serum deprivation. 
Oocytes isolated from prepubertal gilts were matured in vitro, enu‐
cleated, single donor cells were inserted in the perivitelline space, 
and then cell fusion and oocyte activation induced by electric pulse. 
Reconstructed embryos were transferred into the oviducts of hor‐
monally synchronized recipient gilts by mid‐ventral laparotomy.
2.6 | Isolation and culture of peripheral blood 
mononuclear cells
Peripheral blood mononuclear cells (PBMC) from pig and human 
were isolated from blood samples by Ficoll density gradient cen‐
trifugation	 (Biocoll	 Separating	 Solution,	 Biochrom	GmbH).	Human	
blood samples were isolated from anonymized Leukotrap filters 
from the Department of Transfusion Medicine, Hannover Medical 
School.	This	procedure	was	approved	by	the	local	ethics	committee	
of	Hannover	Medical	School.	Human	CD8+ T cells were negatively 
enriched from PBMC by depletion of CD4+ T cells, B cells, NK cells 
and monocytes using magnetic separation with goat anti‐mouse IgG 
beads	 (MACS,	 Miltenyi	 Biotec	 GmbH).	 The	 following	 monoclonal	
antibodies were used to retain unwanted cells: anti‐human HLA‐
DR (L243, ATCC), CD14 (3C10, ATCC), CD56 (T199, provided by T. 
Pietsch, University of Bonn) and anti‐human CD4 (OKT4, ATCC). Cell 
cultures and proliferation assays were performed with RPMI‐1640 
medium	(Lonza)	supplemented	with	10%	FCS,	2	mmol/L	L‐glutamine,	
100 U/mL penicillin, 100 μg/mL streptomycin, 1 mmol/L sodium 
pyruvate and 0.05 mmol/L β‐mercaptoethanol. Cells were cultivated 
at 5% CO2	and	37°C	for	human	PBMC	or	39°C	for	porcine	PBMC.
2.7 | Flow cytometry
For phenotypic analyses of porcine fibroblasts, cells were stained 
with	 anti‐human	 beta‐2‐microglobulin‐PE	 (B2M‐02,	 Santa	
Cruz Biotechnology), an isotype‐matched control antibody (BD 
Biosciences),	 or	 anti‐porcine	 MHC‐I	 (74‐11‐10,	 provided	 by	 A.	
Saalmüller).	Unlabelled	primary	antibody	was	detected	using	FITC‐
labelled goat anti‐mouse Ig as a secondary antibody. Porcine PBMC 
from knockout and wt pigs were stained using anti‐porcine MHC‐I 
(PT85A,	 Kingfisher	 Biotech)	 that	 detected	 the	 constant	α3‐region 
present	in	SLA‐1,	‐2	and	‐3),	or	an	isotype‐matched	control	antibody	
(Dako). α‐1,3Gal expression in PBMC and fibroblasts was detected 
by staining with FITC‐conjugated isolectin B4 (IB4 lectin, isolated 
from Bandeira simplicifolia, Enzo life sciences). FITC‐labelled Dolichos 
biflorus	 lectin	 (DBA	 lectin,	Vector	 laboratories)	was	used	to	detect	
β4GalNT2 activity. Neu5GC epitopes were stained using a poly‐
clonal chicken anti‐Neu5GC antibody (Poly21469, Biolegend) plus 
secondary staining with FITC‐labelled donkey anti‐chicken IgY 
(Jackson	 ImmunoResearch).	Data	were	acquired	on	a	FACSCalibur	
flow cytometer (Becton Dickinson) and analysed with summit 5.1 
software (Beckmann Coulter). Dead cells were excluded from the 
analyses.
2.8 | Western blot analysis
Protein isolation and Western analysis were carried out as described 
previously.5 Neu5Gc epitopes were detected using a purified 
chicken anti‐Neu5Gc antibody (clone Poly21469 chicken IgY; diluted 
1:10 000 in Neu5Gc free blocking solution) and horseradish peroxi‐
dase‐labelled	goat	anti‐chicken	sc‐2428	(diluted	1:5000	in	Neu5Gc	
free blocking solution). GAPDH was detected using mouse monoclo‐
nal	anti‐GAPDH	#G8795,	(diluted	1:3000)	and	rabbit	anti‐mouse	IgG	
H&L	(HRP)	ab6728	(diluted	1:5000).
2.9 | Immunohistochemistry
Immunohistochemistry was performed as described previously.23 
Tissues were snap‐frozen in liquid nitrogen. Five‐micrometre 
cryostat sections were air‐dried, acetone fixed and incubated 
with	mouse	 anti‐pig	MHC	 class	 I	mAb	74‐11‐1024 (provided by A. 
Saalmüller),	or	mouse	anti‐human	beta2	microglobulin	mAb	B2M‐02	
(Thermo	 Fisher	 Scientific),	 then	 horseradish	 peroxidase‐coupled	
goat anti‐mouse antibody (Dianova) and binding visualized with 3‐
amino‐9‐ethyl‐carbazole	 (AEC,	 Sigma).	 Sections	were	 lightly	 coun‐
terstained with haematoxylin (Merck). Cells were stained using 
biotinylated	 anti‐porcine	MHC‐I	 (diluted	1:100;	 PT85A,	Kingfisher	
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Biotech), biotinylated mouse anti‐human beta2 microglobulin mAb 
B2M‐02	 (diluted	 1:100;	 Thermo	 Fisher	 Scientific)	 and	 Atto‐488	
streptavidin (diluted 1:1000; ATTO‐TEC).
2.10 | Cell proliferation
About 1 × 105	human	cells	(CD8+ T cells/ PBMC) were co‐cultured 
in triplicate with increasing numbers of irradiated (30 Gy) porcine 
PBMC from wt or four‐fold knockout pigs in a total of 200 µL me‐
dium in microtiter plates. Tritiated thymidine (3H‐TdR, Perkin Elmer) 
was added after 5 days. After an additional incubation of 16 hours, 
incorporated 3H‐TdR was measured in a Microbeta scintillator coun‐
ter (Wallac).
2.11 | Construction of microfluidic channels with 
round cross section
Microfluidic channels were prepared as described previously.25 In 
brief,	 10	 parts	 of	 polydimethylsiloxane	 (PDMS,	 Sylgard	 184,	 Dow	
Corning) were mixed with 1 part of curing agent and cast in a Petri 
dish	 (Thermo	 Fisher	 Scientific).	 Sterile‐	 and	 pyrogen‐free	 support	
needles	(Ø	120	µm,	Seirin)	were	laid	in	parallel	 in	the	liquid	PDMS	
at the bottom of a petri dish. Four mould needles (Ø 550 µm, BD 
Biosciences)	 were	 placed	 on	 top	 of	 the	 support	 needles	 at	 a	 90°	
angle.	The	Petri	dish	was	incubated	at	60°C	overnight	to	allow	the	
PDMS	to	cure.	PDMS	chips	were	cut	out,	and	the	needles	were	ex‐
tracted horizontally. Inlets and outlets were made using 2 mm biopsy 
punches	(Shoney	Scientific).	Liquid	PDMS	was	used	to	seal	the	nee‐
dle	holes	between	the	edge	of	the	PDMS	gel	and	the	inlet	and	outlet	
and	cured	at	60°C	overnight.	The	final	microfluidic	chips	contained	
four 1 cm long microchannels.
2.12 | PDMS coating and cell seeding in 
microfluidic channels
The luminal surface of the microchannels was coated using human 
fibronectin (Millipore) and bovine collagen I (Gibco, Thermo Fisher 
Scientific),	 as	 described	 previously.25	 Briefly,	 cleaned	 PDMS	 chips	
and standard glass slides were activated with an oxygen plasma 
cleaner (Harrick Plasma) and bonded together. The luminal surface 
of the microchannels was treated with a 5% aqueous solution of 3‐
triethoxysilylpropylamine	(APTES,	Sigma‐Aldrich)	and	incubated	for	
20 minutes at room temperature. The channels were then washed 
with	ultrapure	water	and	treated	with	0.1%	glutaraldehyde	(Sigma‐
Aldrich) for 30 minutes to allow subsequent crosslinking of extracel‐
lular matrix proteins. A 50 µg/mL solution of human fibronectin in 
PBS	was	added,	incubated	for	1	hour	at	37°C,	followed	by	incuba‐
tion with 100 μg/mL of bovine collagen I in 0.2 mol/L acetic acid. 
Unbound collagen I was rinsed from the microchannels with cell cul‐
ture	medium	containing	10%	FBS.	Porcine	kidney	fibroblasts	(PKF)	
grown	to	confluence	 in	T75	flasks	were	disaggregated	with	0.05%	
EDTA‐trypsin	 (Gibco,	 Thermo	 Fisher	 Scientific)	 and	 suspended	 in	
FBS‐supplemented	 cell	 culture	medium	 (DMEM)	with	 4%	 dextran	
from	 Leuconostoc	 spp.	 (Mw	~	 70	 000,	 Sigma‐Aldrich)	 to	 increase	
viscosity and promote cell adhesion. PKF cells were loaded into the 
microfluidic channels at a density of 1 × 106/mL and allowed to reach 
confluence	under	static	conditions	overnight	 in	a	37°C	cell	culture	
incubator.
2.13 | Human serum preparation
Human blood was drawn from healthy volunteers into polypro‐
pylene	 tubes	 containing	 glass	 beads	 (S‐Monovette,	 Sarstedt)	 and	
allowed to clot for 30 minutes at room temperature. The clot was 
removed by centrifugation for 10 minutes, 2000 × g,	 4°C	and	 the	
supernatant	collected	and	stored	at	−80°C.	All	human	blood	samples	
were	obtained	with	informed	consent	according	to	Swiss	jurisdiction	
and the ethics guidelines of the Bern University Hospital.
2.14 | Perfusion of PKFs with normal human serum
A	 peristaltic	 pump	 (Minipuls	 3	 with	 8	 channels,	 Gilson)	 was	 con‐
nected to the PKF‐coated microfluidic channels via sterile silicon 
tubing with stoppers (Gilson) and extension silicon tubes (Gobatec). 
The tubing circuit was previously autoclaved and flushed extensively 
with	distilled	water,	then	PBS	followed	by	cell	culture	medium	with	
4% dextran. Reservoir tubes of 15 mL (Nalge NUNC) were filled 
with 10 mL of either serum‐free DMEM for controls, or 10% normal 
human serum in serum‐free DMEM and connected to each micro‐
channel. PKF‐coated microchannels were perfused at 1 rpm corre‐
sponding	to	a	flow	rate	of	0.09	mL/min	in	an	incubator	at	37°C/	5%	
CO2 for 2 hours. Perfusion was in a closed circuit to recirculate the 
perfusate.
2.15 | Immunoglobulin binding and complement 
deposition assessment
Immunofluorescence staining was performed to assess the bind‐
ing of immunoglobulin (IgG and IgM) and complement activation 
markers (C3b/c and C4b/c). PKFs in the microfluidic channels were 
washed	with	PBS	supplemented	with	calcium	and	magnesium,	fixed	
with	4%	formaldehyde	for	15	minutes	and	blocked	with	PBS‐3%	BSA	
for	45	minutes.	Incubation	with	primary	antibodies	and	4′,6‐diami‐
dino‐2‐phenylindole (DAPI) was carried out at room temperature for 
1 hour. Antibodies used were rabbit anti‐human C3b/c‐fluorescein 
isothiocyanate (FITC, F0201, Dako), rabbit anti‐human C4b/c‐FITC 
(F0169,	Dako),	goat	anti‐human	IgM‐	FITC	(F5384,	Sigma)	and	goat	
anti‐human	IgG‐FITC	(F5512,	Sigma).	Nuclei	were	stained	with	DAPI	
(4′,6‐diamidino‐2‐phenylindole,	 Boehringer,	 Roche	 Diagnostics).	
Images were captured using a Plan‐Apochromat 10×/0.3 
M27/a	=	2.00	mm	objective	with	a	 confocal	 laser‐scanning	micro‐
scope	(LSM	710,	Zeiss)	and	analysed	by	ImageJ	(National	Institutes	
of	Health).	Statistical	analysis	was	performed	using	the	ANOVA	test	
(linear model).
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3  | RESULTS
We adopted two approaches to removing the key porcine xenore‐
active	antigens	and	porcine	SLA‐I	from	the	cell	surface.	Both	used	
multiplex genome editing to introduce inactivating mutations into 
GGTA1, CMAH and B4GALNT2,	while	surface	porcine	SLA‐I	expres‐
sion was blocked by targeting either the light β‐chain (B2M) or the 
constant region of the heavy α‐chain.
3.1 | Generation of pigs with gene‐edited GGTA1, 
CMAH, B4GALNT2 and B2M
Fourteen porcine kidney fibroblast cell clones selected for lack of 
α‐1,3Gal were analysed by DNA sequencing to detect allele‐specific 
mutations of GGTA1, CMAH, B4GALNT2 and B2M. Twelve clones 
(86%)	revealed	at	least	monoallelic	indels	in	all	four	genes,	while	eight	
(57%)	showed	bi‐allelic	mutations	in	all	four	genes,	most	resulting	in	
frameshift	or	premature	 stop	codons.	Selected	clones	were	pooled	
and	used	for	somatic	cell	nuclear	transfer.	A	total	of	680	reconstructed	
embryos were transferred to five recipients, and one pregnancy was 
established	resulting	in	two	live‐born	piglets	(89	and	90).	Ear	clip	sam‐
ples were collected and used for DNA isolation. PCR amplification and 
subsequent	sequencing	of	the	target	sites	revealed	that	piglet	89	had	
compound heterozygous inactivating mutations of GGTA1, B4GALNT2 
and B2M, and a heterozygous knockout of CMAH. This piglet was sac‐
rificed after 4 weeks to isolate cells for further genetic modification. 
Piglet 90 carried compound heterozygous indel mutations in all four 
genes. The target site of GGTA1	exon	7	showed	a	bi‐allelic	11	bp	dele‐
tion. The target site of CMAH exon 10 showed on one allele a single bp 
insertion leading to a frameshift and an early stop codon. The second 
allele carried a 3 bp deletion that eliminated a single amino acid. For 
exon 3 of B4GALNT2, two alleles were identified. One carried a 5 bp 
deletion	and	the	other	a	367	bp	insertion,	both	shifting	the	reading	
frame. Analysis of B2M exon 1 revealed three mutated alleles carrying 
either a 2 bp deletion combined with a T to G mutation, a 53 bp dele‐
tion	or	279	bp	insertion	(Figure	1A).	The	number	of	alleles	detected	
for B2M accorded with previous reports.20,26 The complete indel se‐
quences	of	all	mutated	alleles	are	attached	in	Figure	S3.
3.2 | Multiplex gene editing results in functional 
inactivation of GGTA1, CMAH, B4GALNT2 and B2M
While most gene editing events resulted in frameshift or prema‐
ture stop codons, one CMAH allele showed the loss of a single 
F I G U R E  1   A, Genotype analysis of the four‐fold knockout piglet 90. PCR and sequencing across the target sites for GGTA1, CMAH, 
B4GALNT2 and B2M revealed several indels. A1: allele one, A2: allele two, A3: allele three, WT: wild‐type. B, Piglet 90 aged 4 wk. C, Flow 
cytometry analysis of ECFs revealed the absence of α‐1,3Gal (GGTA1),	Sd(a)	(B4GALNT2),	B2M	(antibody:	B2M‐02)	and	SLA‐I	(antibody:	
74‐11‐10).	Total	cell	count	was	10	000.	Maximum	peak	at	250‐750	cells.	X	axis	from	1	to	104. Light grey histograms represent unstained 
controls, dark grey histograms represent secondary antibody staining only and squared histograms isotype controls. Wild‐type (WT) ear clip 
fibroblasts were used as a positive control. D, Neu5Gc (smear) and GAPDH (35 kDa) were detected by Western blot analysis. Proteins were 
isolated from lung and kidney of piglet 90, and a wild‐type control. GAPDH was used as loading control
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amino acid, which might not perturb its function. Therefore, ear 
clip fibroblasts (ECF) of piglet 90 were isolated, cultured and used 
to confirm functional inactivation of all four genes. Loss of cell 
surface α‐1,3Gal	(detected	by	IB4),	Sd(a)	(detected	by	DBA),	B2M	
and	SLA‐I	antigens	was	confirmed	by	flow	cytometry	(Figure	1C).	
Because Neu5Gc can be transmitted by serum components to 
Neu5Gc‐deficient cells during cultivation, ear fibroblasts from 
piglet 90 were also cultured in xenoserum‐free conditions (serum 
replacement or chicken serum); however, the cells did not prolifer‐
ate and could not be used for Neu5Gc flow cytometry analysis. 
Piglet 90 suffered from an infection at age 6 weeks and had to be 
sacrificed. Necropsy examination revealed no abnormalities other 
than an enlarged spleen due to the infection. Tissue samples were 
collected and Western blot analysis performed to verify the ab‐
sence of Neu5Gc epitopes (Figure 1D).
3.3 | Generation of pigs with gene edited GGTA1, 
CMAH, B4GALNT2 and constant region of the SLA‐I 
heavy α‐chain
For the inactivation of GGTA1, CMAH, B4GALNT2	and	SLA‐I	heavy	
α‐chain, a puromycin‐selected pool was used to enrich α‐1,3 
F I G U R E  2  A,	Genotypic	analysis	of	four‐fold	knockout	(SLA‐I	heavy)	piglets	10261	and	10262.	PCR	and	subsequent	sequencing	of	the	
target sites for GGTA1, CMAH, B4GALNT2	and	SLA‐I	revealed	several	indels.	A1:	allele	one,	A2:	allele	two,	WT:	wild‐type.	Both	pigs	showed	
an	identical	indel	pattern.	For	SLA‐I,	a	PCR	fragment	could	only	be	amplified	for	SLA‐1. B, Flow cytometry analysis of PBMC. Total cell 
count	was	10	000.	Maximum	peak	at	250‐750	cells.	X	axis	from	1	to	104.	Wild‐type	PBMC	from	animals	10269,	10270	and	10274	served	as	
controls. Flow cytometry measurements revealed the absence of α‐1,3Gal (GGTA1), Neu5Gc (CMAH),	Sd(a)	(B4GALNT2)	and	SLA‐I	(antibody:	
PT85A).	Light	grey	histograms	represent	unstained	controls,	dark	grey	histograms	represent	secondary	antibody	staining	only	and	squared	
histograms represent isotype controls. 1 × 105	purified	human	CD8+ T cells (C) or human PBMC (D) were stimulated with increasing numbers 
of irradiated (30 Gy) porcine PBMC from four‐fold knockout pig 10261 or a wild‐type pig. Proliferation was measured after 5 d + 16 h by 3H‐
thymidine	incorporation.	Data	represent	mean	cpm	±	SEM	of	triplicate	cultures	obtained	with	cells	from	one	human	blood	donor	in	a	single	
experiment.	Similar	response	patterns	were	observed	using	responder	cells	from	a	second	blood	donor	and	stimulator	cells	from	four‐fold	
knockout	pig	10262.	Proliferation	of	human	CD8+ T cells decreased after stimulation with four‐fold knockout porcine PBMC
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Gal‐deficient	 cells	via	magnetic	bead	 selection.	Sequencing	across	
the gRNA target sites revealed indel efficiencies of 99% for GGTA1 
and	up	to	81%	for	the	other	targeted	genes.	The	cell	pool	was	used	
for somatic cell nuclear transfer. A total of 436 reconstructed em‐
bryos were transferred into three recipients, and one pregnancy was 
established and two live‐born piglets obtained (10261 and 10262). 
Tail samples were collected and DNA isolated. PCR amplification and 
subsequent sequencing of the target sites revealed bi‐allelic indel 
mutations in all four genes (Figure 2A). Both pigs showed the same 
indel pattern and thus probably originated from the same cell clone. 
The target site of GGTA1	exon	7	showed	a	bi‐allelic	1	bp	insertion.	
The target site of CMAH exon 10 revealed a 4 bp deletion in one 
allele and a 22 bp deletion, 6 bp mutation in the other. B4GALNT2 
showed	a	1	bp	insertion	in	both	alleles.	Analysis	of	SLA‐I	was	only	
possible for SLA‐1 because several PCR primer combinations failed 
to amplify a PCR fragment from SLA‐2 and SLA‐3	 (Figure	S4),	even	
though the original wild‐type cells did amplify fragments. Thus, the 
most likely reason is a deletion that either removed SLA‐2 and SLA 
‐3 sequences or at least the primer‐binding site(s). Analysis of SLA‐1 
exon	4	revealed	a	1	bp	deletion	and	58	bp	inversion.	The	complete	
indel	sequence	of	all	mutated	alleles	can	be	found	in	Figure	S3.
Loss of α‐1,3Gal (GGTA1), Neu5Gc (CMAH),	Sd(a)	(B4GALNT2) and 
SLA‐I	 epitopes	 (detection	of	 SLA‐1,	 SLA‐2	 and	SLA‐3	by	 the	 anti‐
body used) was confirmed by flow cytometry analysis of PBMC from 
piglets 10261 and 10262 (Figure 2B).
3.4 | CD8+ T‐cell response
As human T cells can be activated by porcine cells, a direct inter‐
action between porcine MHC molecules and the human T‐cell re‐
ceptor was assumed.27	Absence	of	SLA‐I	from	porcine	cells	should	
therefore	 lead	 to	 decreased	 activation,	 especially	 of	 human	CD8+ 
T cells. We tested the potential of PBMC from the four‐fold knock‐
out pigs 10261 and 10262 to induce proliferation of either isolated 
purified	 hCD8+ T cells, or total PBMC from human blood donors. 
Using	purified	hCD8+ T cells as responders, almost no proliferation 
was observed after coculture with four‐fold knockout porcine cells, 
compared to a strong proliferative response after stimulation with 
wild‐type porcine cells (Figure 2C). In contrast, only a non‐significant 
difference was observed in the proliferative response of the whole 
human PBMC population stimulated with wild‐type or four‐fold 
knockout cells. The strong proliferating response of hCD4+ T cells 
seemed	to	obscure	any	effect	on	hCD8+ T cells in this culture assay 
(Figure 2D).
3.5 | Immunohistology
Cell and tissue samples were also used to carry out immunohistol‐
ogy	for	B2M	and	SLA‐I	antigens,	see	Figure	3	and	Figure	S5.	Figure	3	
shows kidney fibroblasts of piglet 90 and ear clip fibroblasts of pigs 
10261 and 10262. This verified functional knockout of B2M in animal 
90	 and	 the	 lack	 of	 SLA‐I	molecules	 on	 the	 cell	 surface.	However,	
analysis of heart tissue showed a positive signal for what were prob‐
ably	intracellular	SLA‐I	molecules.	As	the	B2M knockout affects only 
the light β‐chain and not the heavy α‐chain	of	SLA‐I,	it	seems	prob‐
able that the α‐chain accumulates in the cell cytoplasm, as shown 
in mice,28 which would explain the diffuse background signal from 
the	antibody	(Figure	S5).	This	accords	with	the	flow	cytometry	result	
of	 animal	 90,	which	 detected	 no	 SLA‐I	molecules	 on	 the	 cell	 sur‐
face.	Staining	of	SLA‐I	molecules	on	cells	of	pigs	10261	and	10262	
showed	no	SLA‐I	molecules	on	the	cell	surface,	which	also	accords	
with the flow cytometry results.
3.6 | Analysis of off‐target events
We screened for five of the most probable off‐target sites for each of 
the	guide	RNAs,	as	predicted	by	the	program	CRISPOR	(crispor.tefor.
net). Details of screening primers and off‐target sites are provided 
in	Table	S2.	No	off‐target	events	were	detected	for	the	guide	RNAs	
targeting GGTA1, CMAH, B4GALNT2	 and	SLA‐I	 (guide	RNA	1).	 For	
SLA‐I	guide	RNA	2,	one	off‐target	event	was	detected—a	137	bp	in‐
sertion in an intergenic region between the loci PRKCDBP	(CAVIN3)	
and FAM160A2 on chromosome 9. No genes or miRNAs are anno‐
tated in this region of the porcine genome.
F I G U R E  3   Immunofluorescence	detection	of	B2M	and	SLA‐I	on	porcine	kidney	fibroblasts.	B2M	was	detected	using	Biolegend	clone	
2M2‐biotinylated	antibody	(1:100),	and	SLA‐I	using	PT85A‐biotinylated	antibody	(1:100).	Both	were	stained	with	Atto488‐streptavidin	
(1:1000).	Shown:	porcine	kidney	fibroblasts	(PKF)	from	animal	90.	Ear	clip	fibroblasts	(ECF)	of	animals	10261	and	10262.	Scale	bar:	20	µm
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3.7 | Effect of removing different xenoreactive 
epitopes combined with expression of complement 
regulator genes on antigen deposition
To evaluate the effects of different knockout combinations on human 
IgG and IgM binding, we perfused porcine kidney fibroblasts previ‐
ously isolated from our breeding animals that carried CMAH knockout, 
CMAH/GGTA1 double knockout, CMAH/GGTA1/B4GALNT2/B2M four‐
fold knockout (piglet 90) and wild‐type controls, each between passage 
5 to 10 and cultured in artificial round section microvessels perfused 
with normal human serum. CMAH and CMAH/GGTA1 knockout cells 
showed significantly reduced human IgG and IgM binding compared 
to wild type, but four‐fold knockout cells showed the strongest total 
reduction (Figure 4A and B). As antibody binding leads to complement 
activation, we also used the microfluidic system to evaluate the effect 
of combining four‐fold knockout with strong expression of complement 
regulatory transgenes. For this, multiplex genome editing was carried 
out in kidney fibroblasts, passage 5 to 10, from multi‐transgenic pigs 
(human CD46, CD55, CD59, HO1 and A20).5 The knockout profile of 
these cells was analysed after selection and enrichment by TIDE analy‐
sis and indicated almost 100% editing efficiency for each of these four 
genes. The five‐fold transgenic cells showed significant reduction in 
C3b/c and C4b/c activation even in the absence of GGTA1 knockout. 
Inclusion of GGTA1 knockout to this multi‐transgenic background re‐
duced complement activation to a minimum. This reduction was so 
marked that further effects of the four‐fold knockout could not be dis‐
cerned (Figure 4C and D). However, this does not indicate that additional 
knockouts are superfluous for complement activation, as other assays 
or in vivo experiments could very likely reveal additional beneficial ef‐
fects. The amount of IgG and IgM binding was also assessed in five‐fold 
transgenic cells with various numbers of gene knockouts and revealed 
reduced	antibody	binding	with	increased	knockouts	(Figure	S6).
4  | DISCUSSION
Removal of xenoreactive porcine carbohydrate antigens combined 
with expression of xenoprotective transgenes holds the promise 
of protecting xenografts against immune rejection in the short and 
medium term. The most effective combination of knockouts and 
transgenes does however remain to be identified and will likely 
be informed by clinical findings. Previously, we showed that mul‐
tiple transgenes could be combined and placed at a single genetic 
locus.5,23 Here we show that multiple xenoreactive antigens can be 
inactivated simultaneously and, if required, multi‐modified cells can 
be used to generate viable pigs.
We chose to combine a three‐fold knockout of genes respon‐
sible for major xenoreactive sugar antigens plus knockout of the 
light β‐chain (B2M) or heavy α‐chain	of	SLA‐I	to	block	surface	SLA‐I	
expression. Additional combination with a panel of five xenopro‐
tective transgenes in cells of an established xenodonor pig line5 re‐
vealed the benefit of combining knockouts and transgenes. We are 
currently producing 5xtg 4xKO pigs by breeding the 4xKO boars 
10261 and 10262 with sows of our established 5xtg GGTA1, CMAH 
KO line and living offspring can also be produced by nuclear trans‐
fer.	The	boars	10261	and	10262	are	currently	7.5	months	old	and	
housed	in	a	SFP	facility.	Housing	should	however	also	be	possible	in	
a normal breeding facility. The health problems we observed in pig 
90 seem to have been a result of minor stress caused by relocation 
to another compartment in our facility. In future, such transfers can 
be minimized or antibiotic treatment provided during the critical 
timeframe.
While, as previously demonstrated, the three‐fold knockout pro‐
vided beneficial reduction of human immunoglobulin binding,14,17 
but	this	was	further	 improved	by	removing	surface	SLA‐I	antigens	
responsible for HLA cross‐reactivity.17 We chose to inactivate the 
light β‐chain (B2M) or heavy α‐chain	of	SLA‐I.	Although	negative	ef‐
fects of B2M knockout concerning iron homeostasis have been re‐
ported in mice,29 we obtained viable pigs by both methods. Which 
form	of	SLA‐I	inactivation	is	the	best	is	open	to	question.	It	has	been	
shown in mice that B2M‐independent assembly of the heavy α‐chain 
with peptides,30 stably expressed at the cell surface31 and interac‐
tion	with	CD8+ T cells, is possible.30 However, we did not detect cell 
surface	SLA‐I	heavy	α‐chain in B2M knockout pigs by flow cytome‐
try, rather it seems that the α‐chain accumulates in the cytoplasm. 
On the other hand, inactivation of the α‐chain without modification 
of B2M could result in endogenous porcine B2M interacting with 
human HLAI heavy α‐chain after xenotransplantation, and the for‐
mation of new xenoreactive hybrid complexes.32 Future develop‐
ment	might	thus	require	deletion	of	both	the	light	and	heavy	SLA‐I	
chains	to	generate	pigs	lacking	an	SLA‐I	immune	system	to	form	the	
basis for completely MHC‐I humanized pigs and a new generation of 
xenodonor animals.
We previously showed that multiple transgenes can be com‐
bined and placed at a single genetic locus; here we show that mul‐
tiple xenoreactive antigens can be inactivated simultaneously and 
viable pigs generated. This allows fast track generation of xenodo‐
nor pigs once the most effective combination of gene addition and 
inactivation	has	been	determined.	Such	an	approach	also	lends	itself	
to the generation of different pig lines each with a set of genetic 
modifications tailored to the transplantation of particular organs or 
tissues.
F I G U R E  4   Incubation of wild‐type and various knockout porcine cells with human serum using microfluidic channels. A, Binding of 
human	IgG	antibodies.	Mean	±	SD.	Numbers	of	replicates	of	each	group	as	shown	on	X	axis:	N	=	5,	5,	5,	5,	5,	7,	5,	5.	B,	Binding	of	human	
IgM	antibodies.	Mean	±	SD.	N	=	5,	5,	10,	10,	10,	10,	5,	5.	C,	C3b/c	complement	activation.	Mean	±	SD.	N	=	5,	5,	5,	3,	5,	3,	5,	5.	D,	C4b/c	
complement	activation.	Mean	±	SD.	N	=	5,	5,	5,	4,	5,	3,	5,	5.	Micrographic	images	are	on	the	right	side.	NHS:	normal	human	serum;	5xtg:	
cells isolated from pigs expressing CD46, CD55, CD59, HO1 and A20; 4xKO: cells isolated from pigs with inactivation of GGTA1, CMAH, 
B4GALNT2 and B2M. The 4xKO was performed on 5xtg cells
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